Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  08/19/2009
 
Trade Name:  HIBERIX
 
Generic or Proper Name (*):  Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) *
 
Indications Studied:  Active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b
 
Therapeutic Category:  Preventive Vaccine
 
Ages Studied:  15 -19 months
 
Study #:  1
 
Study Type:  Immunogenicity
 
Study Design:  Open Label
 
No Patients:  64
 
No Centers:  4
 
No Countries:  1
 
BPCA(B), PREA(P):  P
 
-
-